Specification
| Pharmaceutical form | White powder in glass ampoules of 1000 iu. Each ampoule is secured in a plastic clip for 5 ampoules. 5 ampoules are packed in a cardboard box in a fixer together with an enclosed leaflet. |
| Active ingredient | Chorionic Gonadotropin 1000 iu. |
| Pharmacotherapeutic group | Hormones of the hypothalamus |
Therapeutic indications
| Human chorionic gonadotropin (HCG) is a gonadotropic hormone that is produced by the placenta during pregnancy and then excreted unchanged by the kidneys. To obtain the drug, it is extracted from urine and purified. It is necessary for the normal growth and maturation of gametes in women and men, as well as for the production of sex hormones. |
Abstract
Tradename
Chorionic Gonadotropin
Dosage form
Lyophilisate for the preparation of solution for intramuscular administration 1000 iu.
Description
A dry, amorphous, porous mass, compacted into a tablet, white or almost white powder.
Structure
1000 iu of powder contains:
Active ingredient: Chorionic Gonadotropin 1000 iu.
Auxiliary components: Mannitol 20 mg.
Pharmacotherapeutic group
Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists.
Pharmacological properties
Human chorionic gonadotropin (HCG) is a gonadotropic hormone that is produced by the placenta during pregnancy and then excreted unchanged by the kidneys. To obtain the drug, it is extracted from urine and purified. It is necessary for the normal growth and maturation of gametes in women and men, as well as for the production of sex hormones.
Indications for use
In men: Hypogonadotropic hypogonadism. Delayed puberty due to insufficiency of the gonadotropic function of the pituitary gland. Cryptorchidism not due to anatomical obstruction. Insufficiency of spermatogenesis, oligoasthenospermia, azoospermia. When conducting a differential diagnostic test for anorchism and cryptorchidism in boys. When conducting a functional Leydig test to assess testicular function in hypogonadotropic hypogonadism before starting long-term stimulating treatment.
In women: Ovarian dysfunction (anovulatory), amenorrhea. Maintenance of the corpus luteum phase.
Method of administration and dosage
After adding the solvent to the lyophilisate, the reconstituted solution of human chorionic gonadotropin is administered intramuscularly, slowly. The prepared solution is not subject to storage, since further preservation of the sterility of the solution is not guaranteed.
In men: In case of hypogonadotropic hypogonadism — 1000–2000 IU of the drug 2–3 times a week, the course of treatment should last at least 3 months. In case of delayed puberty caused by insufficiency of the gonadotropic function of the pituitary gland — 1500 IU 2–3 times a week. The course of treatment is at least 6 months.
In women: In anovulatory cycles, human chorionic gonadotropin is prescribed starting from the 10th to 12th day of the menstrual cycle at 3000 IU 2-3 times with an interval of 2-3 days or 1500 IU 6-7 times every other day. To maintain the corpus luteum phase, two to three repeated injections of the drug can be given at a dose of 1500 IU to 5000 IU each for 9 days after ovulation or embryo transfer (e.g., on days 3, 6, and 9 after ovulation).
Side effects
Immune system disorders. Generalized rash or fever may occur in rare cases. General disorders and administration site disorders. Metabolic and nutritional disorders. Edema. Mental disorders. Irritability, anxiety, depression. Acne. Headache, dizziness. Precocious puberty. Genital and mammary gland disorders.
Contraindication
Hypersensitivity to HCG or any component of the drug. Hormone-dependent malignant tumors of the genitals and mammary gland. Organic lesions of the central nervous system (pituitary tumors, hypothalamus). Deep vein thrombophlebitis. Hypothyroidism.
Overdose
Human chorionic gonadotropin is characterized by extremely low toxicity. In women, overdose may cause ovarian hyperstimulation syndrome In men, gynecomastia may develop; behavioral changes similar to those observed during the first phase of puberty are possible; degeneration of the sex glands, atrophy of the seminiferous tubules; a decrease in the number of spermatozoa in the ejaculate.
Precautions
Persons with risk factors for thrombosis (personal or family history, severe obesity or thrombophilia). In men and boys with latent or overt heart failure, renal dysfunction, arterial hypertension, epilepsy or migraine (or with a history of these conditions); in prepubertal boys; in patients with bronchial asthma.
Interaction with other medicinal products
Concomitant use of Human Chorionic Gonadotropin with high doses of glucocorticosteroids should be avoided. No other drug interactions have been reported.
Special instructions
Treatment with chorionic gonadotropin may sporadically cause gynecomastia; prostate hyperplasia, penile enlargement, increased sensitivity of the nipples of the mammary glands in men, enlargement of the testicles in the inguinal canal in cryptorchidism. The use of gonadotropin increases the risk of developing venous or arterial thromboembolism, so it is necessary to evaluate the benefits of in vitro fertilization therapy in patients at risk. If any of the side effects listed in the instructions worsen, or you notice any other side effects not listed in the instructions, tell your doctor.
Use during pregnancy and lactation
This drug should not be used during pregnancy and lactation.
During pregnancy, the drug can cause virilization in female fetuses. In accordance with the adverse reactions that may occur in infants, it is necessary to decide whether to stop breastfeeding or stop taking the drug.
Influence on the ability to drive vehicles and work with mechanisms
Does not affect.
Storage conditions
Store in a dry, dark place at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life
2 years. Do not use after the expiration date printed on the package.
Vacation conditions
On prescription.
Packaging
White powder in glass ampoules of 1000 iu. Each ampoule is secured in a plastic clip for 5 ampoules. 5 ampoules are packed in a cardboard box in a fixer together with an enclosed leaflet.
Chorionic Gonadotropin
Dosage form
Lyophilisate for the preparation of solution for intramuscular administration 1000 iu.
Description
A dry, amorphous, porous mass, compacted into a tablet, white or almost white powder.
Structure
1000 iu of powder contains:
Active ingredient: Chorionic Gonadotropin 1000 iu.
Auxiliary components: Mannitol 20 mg.
Pharmacotherapeutic group
Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists.
Pharmacological properties
Human chorionic gonadotropin (HCG) is a gonadotropic hormone that is produced by the placenta during pregnancy and then excreted unchanged by the kidneys. To obtain the drug, it is extracted from urine and purified. It is necessary for the normal growth and maturation of gametes in women and men, as well as for the production of sex hormones.
Indications for use
In men: Hypogonadotropic hypogonadism. Delayed puberty due to insufficiency of the gonadotropic function of the pituitary gland. Cryptorchidism not due to anatomical obstruction. Insufficiency of spermatogenesis, oligoasthenospermia, azoospermia. When conducting a differential diagnostic test for anorchism and cryptorchidism in boys. When conducting a functional Leydig test to assess testicular function in hypogonadotropic hypogonadism before starting long-term stimulating treatment.
In women: Ovarian dysfunction (anovulatory), amenorrhea. Maintenance of the corpus luteum phase.
Method of administration and dosage
After adding the solvent to the lyophilisate, the reconstituted solution of human chorionic gonadotropin is administered intramuscularly, slowly. The prepared solution is not subject to storage, since further preservation of the sterility of the solution is not guaranteed.
In men: In case of hypogonadotropic hypogonadism — 1000–2000 IU of the drug 2–3 times a week, the course of treatment should last at least 3 months. In case of delayed puberty caused by insufficiency of the gonadotropic function of the pituitary gland — 1500 IU 2–3 times a week. The course of treatment is at least 6 months.
In women: In anovulatory cycles, human chorionic gonadotropin is prescribed starting from the 10th to 12th day of the menstrual cycle at 3000 IU 2-3 times with an interval of 2-3 days or 1500 IU 6-7 times every other day. To maintain the corpus luteum phase, two to three repeated injections of the drug can be given at a dose of 1500 IU to 5000 IU each for 9 days after ovulation or embryo transfer (e.g., on days 3, 6, and 9 after ovulation).
Side effects
Immune system disorders. Generalized rash or fever may occur in rare cases. General disorders and administration site disorders. Metabolic and nutritional disorders. Edema. Mental disorders. Irritability, anxiety, depression. Acne. Headache, dizziness. Precocious puberty. Genital and mammary gland disorders.
Contraindication
Hypersensitivity to HCG or any component of the drug. Hormone-dependent malignant tumors of the genitals and mammary gland. Organic lesions of the central nervous system (pituitary tumors, hypothalamus). Deep vein thrombophlebitis. Hypothyroidism.
Overdose
Human chorionic gonadotropin is characterized by extremely low toxicity. In women, overdose may cause ovarian hyperstimulation syndrome In men, gynecomastia may develop; behavioral changes similar to those observed during the first phase of puberty are possible; degeneration of the sex glands, atrophy of the seminiferous tubules; a decrease in the number of spermatozoa in the ejaculate.
Precautions
Persons with risk factors for thrombosis (personal or family history, severe obesity or thrombophilia). In men and boys with latent or overt heart failure, renal dysfunction, arterial hypertension, epilepsy or migraine (or with a history of these conditions); in prepubertal boys; in patients with bronchial asthma.
Interaction with other medicinal products
Concomitant use of Human Chorionic Gonadotropin with high doses of glucocorticosteroids should be avoided. No other drug interactions have been reported.
Special instructions
Treatment with chorionic gonadotropin may sporadically cause gynecomastia; prostate hyperplasia, penile enlargement, increased sensitivity of the nipples of the mammary glands in men, enlargement of the testicles in the inguinal canal in cryptorchidism. The use of gonadotropin increases the risk of developing venous or arterial thromboembolism, so it is necessary to evaluate the benefits of in vitro fertilization therapy in patients at risk. If any of the side effects listed in the instructions worsen, or you notice any other side effects not listed in the instructions, tell your doctor.
Use during pregnancy and lactation
This drug should not be used during pregnancy and lactation.
During pregnancy, the drug can cause virilization in female fetuses. In accordance with the adverse reactions that may occur in infants, it is necessary to decide whether to stop breastfeeding or stop taking the drug.
Influence on the ability to drive vehicles and work with mechanisms
Does not affect.
Storage conditions
Store in a dry, dark place at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life
2 years. Do not use after the expiration date printed on the package.
Vacation conditions
On prescription.
Packaging
White powder in glass ampoules of 1000 iu. Each ampoule is secured in a plastic clip for 5 ampoules. 5 ampoules are packed in a cardboard box in a fixer together with an enclosed leaflet.